ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more
ALTEOGEN Inc (196170) - Net Assets
Latest net assets as of September 2025: ₩377.92 Billion KRW
Based on the latest financial reports, ALTEOGEN Inc (196170) has net assets worth ₩377.92 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩639.48 Billion) and total liabilities (₩261.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩377.92 Billion |
| % of Total Assets | 59.1% |
| Annual Growth Rate | 22.56% |
| 5-Year Change | 108.97% |
| 10-Year Change | 610.99% |
| Growth Volatility | 35.71 |
ALTEOGEN Inc - Net Assets Trend (2014–2024)
This chart illustrates how ALTEOGEN Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ALTEOGEN Inc (2014–2024)
The table below shows the annual net assets of ALTEOGEN Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩274.09 Billion | +85.39% |
| 2023-12-31 | ₩147.84 Billion | -0.62% |
| 2022-12-31 | ₩148.76 Billion | +8.80% |
| 2021-12-31 | ₩136.73 Billion | +4.25% |
| 2020-12-31 | ₩131.16 Billion | +87.42% |
| 2019-12-31 | ₩69.98 Billion | +5.04% |
| 2018-12-31 | ₩66.63 Billion | +67.21% |
| 2017-12-31 | ₩39.85 Billion | -11.90% |
| 2016-12-31 | ₩45.23 Billion | +17.32% |
| 2015-12-31 | ₩38.55 Billion | +7.61% |
| 2014-12-31 | ₩35.82 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ALTEOGEN Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5748.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩76.87 Billion | 28.10% |
| Common Stock | ₩26.66 Billion | 9.74% |
| Other Components | ₩170.06 Billion | 62.16% |
| Total Equity | ₩273.59 Billion | 100.00% |
ALTEOGEN Inc Competitors by Market Cap
The table below lists competitors of ALTEOGEN Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Applied Industrial Technologies
NYSE:AIT
|
$9.65 Billion |
|
Everest Group Ltd
NYSE:EG
|
$9.67 Billion |
|
King Yuan Electronics Co Ltd
TW:2449
|
$9.68 Billion |
|
Huagong Tech Co Ltd
SHE:000988
|
$9.70 Billion |
|
APA Corporation
NASDAQ:APA
|
$9.63 Billion |
|
Lite-On Technology Corp
TW:2301
|
$9.62 Billion |
|
Xero Limited
PINK:XROLF
|
$9.62 Billion |
|
GameStop Corp.
NYSE:GME
|
$9.62 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALTEOGEN Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 148,114,262,930 to 273,593,211,290, a change of 125,478,948,360 (84.7%).
- Net income of 62,252,319,000 contributed positively to equity growth.
- Share repurchases of 27,142,861,730 reduced equity.
- New share issuances of 12,713,385,860 increased equity.
- Other factors increased equity by 77,656,105,230.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩62.25 Billion | +22.75% |
| Share Repurchases | ₩27.14 Billion | -9.92% |
| Share Issuances | ₩12.71 Billion | +4.65% |
| Other Changes | ₩77.66 Billion | +28.38% |
| Total Change | ₩- | 84.72% |
Book Value vs Market Value Analysis
This analysis compares ALTEOGEN Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 69.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 292.63x to 69.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1211.42 | ₩354500.00 | x |
| 2017-12-31 | ₩1053.24 | ₩354500.00 | x |
| 2018-12-31 | ₩1756.56 | ₩354500.00 | x |
| 2019-12-31 | ₩1678.64 | ₩354500.00 | x |
| 2020-12-31 | ₩3113.74 | ₩354500.00 | x |
| 2021-12-31 | ₩3232.11 | ₩354500.00 | x |
| 2022-12-31 | ₩2888.81 | ₩354500.00 | x |
| 2023-12-31 | ₩2862.27 | ₩354500.00 | x |
| 2024-12-31 | ₩5133.55 | ₩354500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ALTEOGEN Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.75%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 60.52%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.49x
- Recent ROE (22.75%) is above the historical average (-1.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 2.60% | 13.22% | 0.19x | 1.06x | ₩-2.65 Billion |
| 2015 | 3.13% | 25.57% | 0.12x | 1.02x | ₩-2.65 Billion |
| 2016 | -7.93% | -52.42% | 0.14x | 1.06x | ₩-8.11 Billion |
| 2017 | -18.69% | -61.54% | 0.28x | 1.08x | ₩-11.43 Billion |
| 2018 | -10.31% | -50.15% | 0.19x | 1.07x | ₩-13.53 Billion |
| 2019 | -1.01% | -2.41% | 0.34x | 1.23x | ₩-7.70 Billion |
| 2020 | -0.74% | -2.29% | 0.27x | 1.21x | ₩-14.09 Billion |
| 2021 | 4.39% | 14.59% | 0.16x | 1.90x | ₩-7.67 Billion |
| 2022 | -5.48% | -28.28% | 0.12x | 1.65x | ₩-23.02 Billion |
| 2023 | -2.28% | -3.49% | 0.38x | 1.73x | ₩-18.18 Billion |
| 2024 | 22.75% | 60.52% | 0.25x | 1.49x | ₩34.89 Billion |
Industry Comparison
This section compares ALTEOGEN Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALTEOGEN Inc (196170) | ₩377.92 Billion | 2.60% | 0.69x | $9.64 Billion |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |